

# Ken AndrÃ© Olausson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3887507/publications.pdf>

Version: 2024-02-01

40  
papers

4,117  
citations

257450

24  
h-index

265206

42  
g-index

42  
all docs

42  
docs citations

42  
times ranked

5798  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 242-255.	7.0	114
2	The ‘Guardian of the Genome’ An Old Key to Unlock the ERCC1 Issue. <i>Clinical Cancer Research</i> , 2019, 25, 2369-2371.	7.0	2
3	A novel antibody-based approach to detect the functional ERCC1-202 isoform. <i>DNA Repair</i> , 2018, 64, 34-44.	2.8	7
4	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. <i>ESMO Open</i> , 2018, 3, e000257.	4.5	62
5	Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2995-3006.	1.6	223
6	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 416-427.	2.8	11
7	DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 1671-1687.	8.2	19
8	MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer. <i>Cancer Biomarkers</i> , 2016, 17, 323-333.	1.7	7
9	Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 483.	2.6	31
10	Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance. <i>Cell Cycle</i> , 2016, 15, 295-302.	2.6	23
11	No evidence for viral sequences in five lepidic adenocarcinomas (former ‘BAC’) by a high-throughput sequencing approach. <i>BMC Research Notes</i> , 2015, 8, 782.	1.4	3
12	Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 2470-2477.	1.2	20
13	PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?. <i>Current Pharmaceutical Design</i> , 2014, 20, 3875-3882.	1.9	14
14	A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. <i>Oncogene</i> , 2013, 32, 5377-5387.	5.9	83
15	19q13-ERCC1 Gene Copy Number Increase in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 549-557.	2.6	9
16	ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1101-1110.	27.0	342
17	Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. <i>Cell Cycle</i> , 2013, 12, 877-883.	2.6	57
18	Prognostic value of LIPC in non-small cell lung carcinoma. <i>Cell Cycle</i> , 2013, 12, 647-654.	2.6	16

#	ARTICLE	IF	CITATIONS
19	Cisplatin Resistance Associated with PARP Hyperactivation. <i>Cancer Research</i> , 2013, 73, 2271-2280.	0.9	143
20	ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. <i>Cell Cycle</i> , 2013, 12, 3298-3306.	2.6	37
21	Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. <i>Annals of Oncology</i> , 2012, 23, 2245-2252.	1.2	60
22	DNA Repair Capacity in Circulating Lymphocytes and Influence on Platinum Effect in Tumor Cells. <i>Journal of Clinical Oncology</i> , 2012, 30, 1567-1568.	1.6	2
23	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. <i>Cell Reports</i> , 2012, 2, 257-269.	6.4	122
24	The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 144-155.	27.6	96
25	ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ Analysis. <i>American Journal of Pathology</i> , 2011, 178, 69-78.	3.8	59
26	Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. <i>Clinical Cancer Research</i> , 2011, 17, 5562-5572.	7.0	56
27	ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. <i>Annals of Oncology</i> , 2011, 22, 575-581.	1.2	15
28	MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 1206-1215.	7.0	89
29	Expression of Chemokine Receptor CCR6 as a Molecular Determinant of Adrenal Metastatic Relapse in Patients With Primary Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 187-191.	2.6	25
30	Validation of ERCC1-XPF Immunodetection â€“ Letter. <i>Cancer Research</i> , 2010, 70, 3851-3852.	0.9	19
31	A new step ahead for the consideration of ERCC1 as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin. <i>Cancer Biology and Therapy</i> , 2009, 8, 1922-1923.	3.4	8
32	Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. <i>Oncogene</i> , 2009, 28, 4249-4260.	5.9	53
33	Are RAS mutations predictive markers of resistance to standard chemotherapy?. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 528-534.	27.6	79
34	Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 99-117.	4.4	77
35	Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. <i>Annals of Oncology</i> , 2008, 19, 1875-1881.	1.2	45
36	A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Nonâ€“Small Cell Lung Cancer Cells Resistant to Erlotinib. <i>Cancer Research</i> , 2007, 67, 6253-6262.	0.9	121

#	ARTICLE	IF	CITATIONS
37	ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Current Opinion in Pulmonary Medicine, 2007, 13, 284-289.	2.6	79
38	DNA Repair by ERCC1 in Non-“Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. New England Journal of Medicine, 2006, 355, 983-991.	27.0	1,611
39	Telomeres and telomerase as targets for anticancer drug development. Critical Reviews in Oncology/Hematology, 2006, 57, 191-214.	4.4	85
40	Cyclooxygenase-2 as a target for anticancer drug development. Critical Reviews in Oncology/Hematology, 2006, 59, 51-64.	4.4	186